^
    2years
    FGFR1 Is a Novel Therapeutic Target in Relapsed/Refractory Diffuse Large B Cell Lymphoma (RR-DLBCL) (ASH 2022)
    We then tested the anti-lymphoma effect of the novel selective oral FGFR1 inhibitor SSR128129E (FGFR1i) in two engrafted syngeneic mouse models DLBCL (A20 and Setd2+/-/Bcl2OE) implanted subcutaneously and intrasplenically, respectively, in immunocompetent mice...To test this notion, we assessed the effect of FGFR1i in a murine lymphoma model depleted of macrophages using liposomal clodronate...In conclusion, our results suggest that CAFFGFR1s could constitute a novel LME-resident therapeutic vulnerability in RR-DLBCL and that FGFR1i may require phagocytic TAMs for its anti-lymphoma effect. Given the FDA approval of several FGFR1/2 inhibitors for solid tumors, our results bare translational potential to benefit RR-DLBCL patients in the near term.
    IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • FGFR1 (Fibroblast growth factor receptor 1) • BCL6 (B-cell CLL/lymphoma 6) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CCL2 (Chemokine (C-C motif) ligand 2) • PDX1 (Pancreatic And Duodenal Homeobox 1) • CXCL3 (C-X-C Motif Chemokine Ligand 3)
    |
    EZH2 mutation • FGFR1 expression • SETD2 mutation
    |
    clodronate disodium • SSR 128129